What is the price-to-earnings ratio of Merus?
The price-earnings ratio of Merus is currently 81.99.
Merus P/S 2024
Merus P/S
81.99
Ticker
MRUS
ISIN
NL0011606264
WKN
A2AKFX
As of Sep 13, 2024, Merus's P/S ratio stood at 81.99, a 210.45% change from the 26.41 P/S ratio recorded in the previous year.
The Merus P/S history
Merus Aktienanalyse
What does Merus do?
Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Merus's P/S Ratio
Merus's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Merus's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Merus's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Merus’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Merus stock
How has the price-earnings ratio of Merus changed compared to last year?
The price-to-earnings ratio of Merus has increased by 210.45% increased compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Merus high compared to other companies?
Yes, the price-to-earnings ratio of Merus is high compared to other companies.
How does an increase in the price-earnings ratio of Merus affect the company?
An increase in the price-earnings ratio of Merus would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Merus affect the company?
A decrease in the price-earnings ratio of Merus would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Merus?
Some factors that influence the price-earnings ratio of Merus are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Merus pay?
Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.
What is the dividend yield of Merus?
The current dividend yield of Merus is .
When does Merus pay dividends?
Merus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Merus?
Merus paid dividends every year for the past 0 years.
What is the dividend of Merus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Merus located?
Merus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merus from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Merus pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Merus in the year 2023?
In the year 2023, Merus distributed 0 USD as dividends.
In which currency does Merus pay out the dividend?
The dividends of Merus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Merus
Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
